home All News open_in_new Full Article

Enigma Biomedical USA, Inc. Announces Candidate Selection of Novel 4R Tau PET Imaging Biomarkers

KNOXVILLE, Tenn. — Enigma Biomedical USA, Inc. (EB USA) today announced that it has selected two (2) four-repeat tau (4R Tau) protein PET imaging biomarkers to advance into Phase 1 (Ph1) studies. Previously, EB USA executed an Exclusive License and Option Agreement (License) with AbbVie for the development and potential commercialization of AbbVie’s next-generation F18 […]



Enigma Biomedical USA, Inc. (EB USA) has selected two 4R Tau protein PET imaging biomarkers, licensed from AbbVie, to advance into Phase 1 studies for neurodegenerative disease assessment. The biomarkers aim to aid in understanding tauopathies like Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration. Phase 1 studies will evaluate safety, dosimetry, biomarker dynamics, and optimal imaging time. EB USA aims to expand availability of this imaging technology to the scientific community.

today 9 d. ago attach_file Politics

attach_file Transport
attach_file Society
attach_file Politics
attach_file Other
attach_file Other
attach_file Other
attach_file Events
attach_file Other
attach_file Culture
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Politics
attach_file Other
attach_file Events
attach_file Society
attach_file Other
attach_file Other
attach_file Other


ID: 3417326516
Add Watch Country

arrow_drop_down